Table 1.
The relative a changes of steroids, further predictors and neurotic scores and absolute b changes of neurotic scores after intervention with physical activity (displayed as medians with quartiles). Only significant changes (p < 0.05) are shown.
| Variable | Basal Values | Δr [%] a | p-Value c |
| Age [years] | 58 (55, 61) | --- | --- |
| Pregnenolone [nM] | 0.935 (0.717, 1.18) | 27 (−10.5, 58) | <0.001 |
| Pregnenolone sulfate [nM] | 79.6 (53.1, 106) | 10.8 (−7.23, 25.4) | 0.011 |
| 17-Hydroxypregnenolone [nM] | 1.62 (1.09, 3.02) | 52.4 (−4.44, 151) | <0.001 |
| 17-Hydroxypregnenolone sulfate [nM] | 3.21 (2.18, 5.68) | 41.2 (−9.57, 78.4) | <0.001 |
| 16α-Hydroxypregnenolone [nM] | 0.31 (0.191, 0.493) | 28.8 (−14.6, 88.5) | 0.003 |
| 20α-Dihydropregnenolone [nM] | 1.3 (0.949, 1.93) | 10.6 (−11.8, 21.5) | 0.038 |
| Dehydroepiandrosterone (DHEA) [nM] | 6.75 (4.3, 8) | 24.4 (−3.65, 66) | <0.001 |
| 7α-Hydroxy-DHEA [nM] | 1.2 (0.841, 1.92) | 22.7 (−20.2, 53.7) | 0.003 |
| Androstenediol [nM] | 1.29 (1.02, 1.97) | 11.1 (−3.87, 34.2) | 0.005 |
| 17-Hydroxyprogesterone [nM] | 0.77 (0.502, 1.22) | 43.1 (−23.5, 110) | 0.001 |
| 16α-Hydroxyprogesterone [nM] | 0.458 (0.287, 1.01) | 32.7 (−25.6, 195) | 0.002 |
| Androstenedione [nM] | 3.11 (1.98, 4.16) | 25.6 (−12.6, 76.4) | 0.003 |
| Isopregnanolone sulfate [nM] | 6.04 (4.52, 8.59) | 5.58 (−9.3, 28) | 0.031 |
| Conjugated epipregnanolone [nM] | 1.56 (0.837, 2.43) | 8.84 (−11.6, 40.3) | 0.013 |
| 5α-Pregnane-3α,20α-diol [nM] | 0.0574 (0.0278, 0.114) | 24.3 (−41, 87.6) | 0.034 |
| 17-Hydroxyallopregnanolone [nM] | 0.00813 (0.00426, 0.018) | 30.5 (−55.1, 183) | 0.046 |
| 17-Hydroxyallopregnanolone sulfate [nM] | 0.928 (0.638, 1.53) | 17.6 (−10.7, 40.2) | 0.032 |
| 17-Hydroxypregnanolone [nM] | 0.0365 (0.0132, 0.0743) | 7.65 (−62.3, 135) | 0.035 |
| 17-Hydroxypregnanolone sulfate [nM] | 6.69 (4.56, 9.11) | 18.5 (−7.25, 37.2) | 0.022 |
| Conjugated 5α-pregnane-3α,17α,20α-triol [nM] | 388 (201, 740) | 198 (40.2, 416) | <0.001 |
| Epiandrosterone [nM] | 1.18 (0.838, 1.52) | 21.9 (−16.2, 43.7) | 0.006 |
| Epietiocholanolone sulfate [nM] | 43.6 (23.5, 65.3) | 19.6 (−1.59, 35.5) | <0.001 |
| Conjugated 5β-androstane-3α,17β-diol [nM] | 0.721 (0.389, 1.14) | 15.5 (−13.9, 55.8) | 0.015 |
| Cortisol [nM] | 413 (291, 472) | 24.2 (−5.81, 61.6) | 0.004 |
| Cortisol/DHEAS | 0.183 (0.0928, 0.416) | 20.2 (−12.8, 71.7) | 0.008 |
| Corticosterone [nM] | 12.6 (6.72, 17.5) | 21.9 (−13.7, 129) | <0.001 |
| 5α,20α-Tetrahydrocorticosterone [nM] | 0.0848 (0.0442, 0.193) | 50.8 (−37.8, 254) | 0.001 |
| 5β,20α-Tetrahydrocorticosterone [nM] | 0.433 (0.218, 0.84) | 22.6 (−35.4, 111) | 0.013 |
| 11β-Hydroxyandrostenedione [nM] | 136 (84, 201) | 12.9 (−12.6, 53.7) | 0.008 |
| Somatic symptoms score | 11 (8, 17) | −50 (−72.7, −25) | <0.001 |
| Psychosomatic symptoms score | 15 (11, 23) | −71.4 (−80, −50) | <0.001 |
| Psychiatric symptoms score | 12.5 (5, 18) | −57.3 (−86, −36.1) | <0.001 |
| Overall symptoms score | 39 (28, 57) | −56.8 (−76, −42.1) | <0.001 |
| Absolute Changes of Neurotic Symptoms | Basal Values | Δ b | p-Value a |
| Somatic symptoms score | 11 (8, 17) | −6 (−9, −2) | <0.001 |
| Psychosomatic symptoms score | 15 (11, 23) | −10 (−15, −6) | <0.001 |
| Psychiatric symptoms score | 12.5 (5, 18) | −6 (−10.3, −3) | <0.001 |
| Overall symptoms score | 39 (28, 57) | −21 (−33, −13) | <0.001 |
a Δr represents the relative change calculated as (value after intervention − basal value)/basal value, b Δ represents the absolute change calculated as (value after intervention − basal value); c the significance of changes was evaluated using Wilcoxon’s robust paired test.